Literature DB >> 678427

Immunopathology of angioimmunoblastic lymphadenopathy.

D B Jones, M Castleden, J L Smith, B L Mepham, D H Wright.   

Abstract

Eight patients with angioimmunoblastic lymphadenopathy have been studied by a variety of immunological and pathological techniques. They exhibited a spectrum of immunological reactivities that, in this small series, could be roughly correlated with survival. Those patients with relative B-cell predominance as shown by cell marker studies, histologically showed large numbers of plasma cells, and this pattern was associated in 3 of our patients with a survival of 3 years or more. T-cell predominance or both B- and T-cell depletion was associated histologically with large numbers of blast cells and eosinophils, but with few plasma cells. These patients responded poorly to therapy and had short survival times. One patient with B-cell predominance subsequently died of a histiocytic lymphoma.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 678427      PMCID: PMC2009654          DOI: 10.1038/bjc.1978.153

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  T and B lymphocytes and Reed-Sternberg cells in Hodgkin's disease lymph nodes and spleens.

Authors:  S V Payne; D B Jones; D G Haegert; J L Smith; D H Wright
Journal:  Clin Exp Immunol       Date:  1976-05       Impact factor: 4.330

2.  Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin's disease.

Authors:  R J Lukes; B H Tindle
Journal:  N Engl J Med       Date:  1975-01-02       Impact factor: 91.245

3.  A morphologic study of rabbit bronchial lymphoid aggregates and lymphoepithelium.

Authors:  J Bienenstock; N Johnston
Journal:  Lab Invest       Date:  1976-10       Impact factor: 5.662

4.  Angio-immunoblastic lymphadenopathy with dysproteinaemia.

Authors:  G Frizzera; E M Moran; H Rappaport
Journal:  Lancet       Date:  1974-06-01       Impact factor: 79.321

5.  Distribution of gamma E-forming cells in lymphoid tissues of the human and monkey.

Authors:  T Tada; K Ishizaka
Journal:  J Immunol       Date:  1970-02       Impact factor: 5.422

6.  Postvaccinial lymphadenitis. Hyperplasia of lymphoid tissue that simulates malignant lymphomas.

Authors:  R J Hartsock
Journal:  Cancer       Date:  1968-04       Impact factor: 6.860

7.  Angio-immunoblastic lymphadenopathy terminating as Hodgkin's disease.

Authors:  X Yataganas; C Papadimitriou; G Pangalis; D Loukopoulos; P Fessas; N Papacharalampous
Journal:  Cancer       Date:  1977-05       Impact factor: 6.860

8.  Immunoblastic sarcoma arising in child with immunoblastic lymphadenopathy.

Authors:  C B Howarth; C C Bird
Journal:  Lancet       Date:  1976-10-02       Impact factor: 79.321

9.  Angioimmunoblastic lymphadenopathy in persistent virus infection?

Authors:  G R Krueger; G Konorza
Journal:  Lancet       Date:  1977-11-26       Impact factor: 79.321

10.  Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-vs.-host reaction.

Authors:  Y A Sidky; R Auerbach
Journal:  J Exp Med       Date:  1975-05-01       Impact factor: 14.307

View more
  4 in total

1.  Immunoperoxidase techniques and controls.

Authors:  A G Maciver; B L Mepham
Journal:  J Clin Pathol       Date:  1980-12       Impact factor: 3.411

2.  Immunoglobulin heavy chain patterns in reactive lymphadenopathy.

Authors:  M Sundaresan; T Rhodes; A B Akosa
Journal:  J Clin Pathol       Date:  1991-09       Impact factor: 3.411

3.  Histological, immunohistological and autopsy findings in lymphogranulomatosis X (including angio-immunoblastic lymphadenopathy).

Authors:  H Knecht; E W Schwarze; K Lennert
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

4.  Immuno-histological diagnosis of lymphoproliferative diseases by selected combinations of antisera and monoclonal antibodies.

Authors:  G Janossy; J A Thomas; G Pizzolo; S M Granger; J McLaughlin; J A Habeshaw; A G Stansfeld; J Sloane
Journal:  Br J Cancer       Date:  1980-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.